PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
February 19, 2026Clinical Cancer Research

Abstract PS5-02-08: Impact of Prior T-DM1 Exposure on the Efficacy of Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

FKFatih KemikTST. K. SahinHOH. Ozcelik

Discussion

Loading...

Member takes

Overview

Multicenter study reveals shorter progression-free survival in HER2-positive patients with T-DM1 exposure, suggesting treatment sequencing impacts efficacy.

Key Points

  • To evaluate the impact of prior T-DM1 exposure on the efficacy of trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients.
  • Retrospective cohort study across 21 oncology centers in Turkey
  • Evaluated patients receiving trastuzumab deruxtecan therapy
  • Collected clinical, pathological, and treatment data
  • Used Cox proportional hazards regression for hazard ratio estimates
  • 199 patients were included with a mean age of 45.8 years
  • 47% of patients with prior T-DM1 exposure experienced disease progression after T-DXd compared to 14% without T-DM1 exposure
  • Prior T-DM1 exposure was associated with a higher risk of progression (HR = 3.03)
  • Significantly shorter PFS in T-DM1-pretreated group (median 12.1 months) compared to T-DM1-naive group

Cite This Study

Kemik et al. (2026) studied this question.

synapsesocial.com/papers/6996a85cecb39a600b3eef88https://doi.org/10.1158/1557-3265.sabcs25-ps5-02-08
View Full Paper
Ask AI
Bookmark
Share